sellWeak10b5-1 plan
Vivo Opportunity, LLC sold $2.8M of TERN
owner at Terns Pharmaceuticals, Inc.. 420,663 shares at an average of $6.65, traded Apr 1, 2024, filed Apr 3, 2024.
Warning score
17Value
$2.8M
420,663 shares
Holdings after
268,573
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$2.8M at market
- 0Share of holdings soldSold 9.7% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001213900-24-030020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2024 | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -136,255 | $6.99 | $952k | 4,203,957 | Apr 3, 2024 |
| Apr 1, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -39,411 | $6.99 | $275k | 1,997,146 | Apr 3, 2024 |
| Apr 1, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -5,451 | $6.99 | $38k | 275,772 | Apr 3, 2024 |
| Apr 2, 2024 | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -76,346 | $6.65 | $508k | 4,127,611 | Apr 3, 2024 |
| Apr 2, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -22,084 | $6.65 | $147k | 1,975,062 | Apr 3, 2024 |
| Apr 2, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -3,050 | $6.65 | $20k | 272,722 | Apr 3, 2024 |
| Apr 3, 2024 | SOpen-market sale Common Stockindirect: By Vivo Opportunity Fund Holdings, L.P.10b5-1 | -103,870 | $6.20 | $644k | 4,023,741 | Apr 3, 2024 |
| Apr 3, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Fund VIII, L.P.10b5-1 | -30,047 | $6.20 | $186k | 1,945,015 | Apr 3, 2024 |
| Apr 3, 2024 | SOpen-market sale Common Stockindirect: By: Vivo Capital Surplus Fund VIII, L.P.10b5-1 | -4,149 | $6.20 | $26k | 268,573 | Apr 3, 2024 |
Related signals
Other insiders at Terns Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $50k 942 shares | -1% | |
| 11Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $681k 14,583 shares | -5% | |
| 9Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $572k 14,583 shares | -5% | |
| 28Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2.5M 68,749 shares | -19% | |
| 53Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2.7M 71,339 shares | -34% | |
| 29Weak | Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $45k 1,155 shares | -2% | |
| 17Weak | Terns Pharmaceuticals, Inc. | Jill M. Quigley Sr. Advisor & Strategy Officer | $441k 24,520 shares | -100% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $7,407 944 shares | -2% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $3,640 853 shares | -2% | |
| 51Moderate | Terns Pharmaceuticals, Inc. | Andrew Gengos Chief Financial Officer | $39k 10,000 shares | +67% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.